Deutsche Bank Downgrades ResMed (RMD) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Deutsche Bank Downgrades ResMed (RMD) to Hold
January 25, 2019 7:10 AM EST
JPMorgan analyst David Low downgraded ResMed (RMD:AU) (NYSE: RMD) from Neutral to Underweight with a price target of AUD13.40.
Low notes results were boosted by a one-off benefit. Sales will likely be subdued over much of 2019 as the business cycles... More
January 25, 2019 7:01 AM EST
Goldman Sachs analyst Chris Cooper downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy to Neutral with a price target of AUD15.20 (from AUD16.70).
Cooper said shares were priced for perfection going into the 2Q print and the company delivered a meaningful 3% sales... More
January 24, 2019 4:09 PM EST
ResMed (NYSE: RMD) reported Q2 EPS of $1.00, $0.05 better than the analyst estimate of $0.95. Revenue for the quarter came in at $651.1 million versus the consensus estimate of $672.91 million.
Revenue increased 8% to $651.1 million; up 9% on a constant currency basisGross Margin expanded 70bps to...
More
